TT-10 (10 μmol/L ; 48 h) significantly promoted cell cycle activation and cell division of human induced pluripotent stem cell (hiPSC) derived cardiomyocytes (hiPSCM).[1]

TT-10 (2 μM, 10 μM, 20 μM, or 100 μM ; 48 h ; intraperitoneal injections) was administered to infarcted mouse hearts, the treatment promoted cardiomyocyte proliferation and was associated with declines in infarct size 1 week after administration, but cardiac function worsened at later time points.[2]